Biogen (NASDAQ:BIIB) Announces Earnings Results

Biogen (NASDAQ:BIIB) issued its quarterly earnings data on Thursday. The biotechnology company reported $3.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.26 by ($0.24), Zacks reports. The firm had revenue of $2.43 billion during the quarter, compared to analyst estimates of $2.25 billion. Biogen had a net margin of 16.87% and a return on equity of 14.98%. The firm’s revenue was up 6.2% compared to the same quarter last year. During the same period last year, the business earned $3.67 EPS. Biogen updated its FY 2025 guidance to 14.500-15.500 EPS.

Biogen Price Performance

Shares of BIIB opened at $123.53 on Friday. Biogen has a one year low of $110.04 and a one year high of $238.00. The stock’s fifty day moving average is $130.58 and its 200-day moving average is $147.04. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.35. The firm has a market capitalization of $18.08 billion, a price-to-earnings ratio of 11.04, a price-to-earnings-growth ratio of 1.51 and a beta of 0.13.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Morgan Stanley cut their price objective on shares of Biogen from $157.00 to $152.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 9th. Canaccord Genuity Group cut their price target on Biogen from $265.00 to $220.00 and set a “buy” rating on the stock in a research note on Friday. The Goldman Sachs Group lowered their price objective on Biogen from $219.00 to $197.00 and set a “buy” rating for the company in a research note on Wednesday, April 23rd. Robert W. Baird cut their target price on Biogen from $300.00 to $255.00 and set an “outperform” rating on the stock in a research report on Friday. Finally, Needham & Company LLC reissued a “hold” rating on shares of Biogen in a research report on Friday. Twenty research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, Biogen currently has a consensus rating of “Hold” and an average price target of $195.85.

Insider Buying and Selling

In related news, Director Stephen A. Sherwin sold 8,760 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the sale, the director now owns 11,318 shares of the company’s stock, valued at $1,697,926.36. The trade was a 43.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.16% of the company’s stock.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.